urothelial cancer
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...
DECEMBER 30, 2024
FDA Approves Opdivo Combination for Unresectable or Metastatic Urothelial Carcinoma
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with cisplatin and gemcitabine for ...
MARCH 7, 2024
FDA Approves Padcev with Keytruda for Locally Advanced or Metastatic Urothelial Cancer
The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, ...
DECEMBER 17, 2023
Padcev Approved for Some Patients With Locally Advanced or Metastatic Bladder Cancer
The FDA granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas/Seattle Genetics) for the ...
DECEMBER 20, 2019
New Standards Defined by Key Trials Presented at ASCO
Chicago—The standard of care for subgroups of patients with metastatic pancreatic, urothelial and ...
JULY 29, 2019
